Focused Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-384
Closed -$297K 285
2026
Q1
$297K Buy
+384
New +$294K 0.03% 157
2024
Q2
Sell
-112
Closed -$108K 258
2024
Q1
$108K Buy
112
+101
+918% +$96K 0.02% 177
2023
Q4
$9.44K Sell
11
-15
-58% -$12.4K ﹤0.01% 563
2023
Q3
$21.2K Sell
26
-43
-62% -$33.8K ﹤0.01% 417
2023
Q2
$49.6K Hold
69
0.01% 304
2023
Q1
$56.7K Hold
69
0.01% 285
2022
Q4
$49.8K Hold
69
0.01% 308
2022
Q3
$48K Hold
69
0.01% 285
2022
Q2
$41K Buy
69
+15
+28% +$9.75K 0.01% 309
2022
Q1
$38K Hold
54
0.01% 343
2021
Q4
$34K Hold
54
0.01% 417
2021
Q3
$33K Hold
54
0.01% 434
2021
Q2
$30K Hold
54
0.01% 451
2021
Q1
$26K Hold
54
﹤0.01% 462
2020
Q4
$26K Buy
54
+45
+500% +$24.3K 0.01% 423
2020
Q3
$5K Sell
9
-150
-94% -$91K ﹤0.01% 609
2020
Q2
$99K Buy
159
+150
+1,667% +$85.1K 0.02% 229
2020
Q1
$4K Hold
9
﹤0.01% 553
2019
Q4
$3K Hold
9
﹤0.01% 626
2019
Q3
$2K Sell
9
-120
-93% -$35.5K ﹤0.01% 641
2019
Q2
$40K Buy
129
+120
+1,333% +$40K 0.01% 340
2019
Q1
$4K Hold
9
﹤0.01% 577
2018
Q4
$3K Sell
9
-2,109
-100% -$772K ﹤0.01% 596
2018
Q3
$856K Sell
2,118
-124
-6% -$47.2K 0.29% 61
2018
Q2
$773K Buy
+2,242
New +$701K 0.27% 60
2016
Q4
Sell
-10
Closed -$4K 730
2016
Q3
$4K Hold
10
﹤0.01% 556
2016
Q2
$3K Hold
10
﹤0.01% 570
2016
Q1
$4K Hold
10
﹤0.01% 510
2015
Q4
$5K Buy
+10
New +$5.42K ﹤0.01% 513

Other funds holding REGN

Focused Wealth Management's REGN Position: Q2 2026 in Review

Focused Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 384 shares — an estimated $297K sold.

Focused Wealth Management first reported a position in REGN in Q4 2015 and held it in 29 quarters. The position peaked at $856K in Q3 2018. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Focused Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Focused Wealth Management sold 384 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $297K.
  • Focused Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2015 and held it in 29 quarters.
  • Focused Wealth Management's Regeneron Pharmaceuticals position peaked at $856K in Q3 2018.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Focused Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.